Madrigal Pharmaceuticals Presents Late-Breaking Phase 3 - GlobeNewswire

Retrieved on: 2022-06-26 01:00:41

Tags for this article:

Medical specialties

Clinical medicine

Non-alcoholic fatty liver disease

Cirrhosis

Steatohepatitis

Liver biopsy

Magnetic resonance elastography

Elastography

madrigal pharmaceuticals inc

Click the tags to see associated articles and topics

Madrigal Pharmaceuticals Presents Late-Breaking Phase 3 - GlobeNewswire. View article details on HISWAI: https://www.globenewswire.com/news-release/2022/06/25/2469084/0/en/Madrigal-Pharmaceuticals-Presents-Late-Breaking-Phase-3-NASH-Data-and-Multiple-Oral-Abstracts-at-EASL-s-International-Liver-Congress.html

Excerpt

Late-Breaking Oral Presentation: “Primary data analyses of MAESTRO-NAFLD-1, a 52 week double-blind placebo-controlled phase 3 clinical trial of ...

Article found on: www.globenewswire.com

View Original Article